Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by retiredcopon Mar 16, 2021 11:51am
253 Views
Post# 32807655

RE:RE:RE:RE:RE:RE:Any Idea Why?...

RE:RE:RE:RE:RE:RE:Any Idea Why?...Neither.company has expressed any interesting buying pmn science....if any one does it will be a company that had a failure in their science or a company that sees that lilly and Biogen.are.going to.be the only ones in the market that is.worth billions...that desire.to get.into the market with someone.elses science will be the factor...it.could be as simple as joint.venture on the clinicals with first right of refusal or more.c ommittment of.buying the ad science.or the jackpot...they buy everything pmns owns ...this.could.be the scenario for pd and Als...but we may be forgetting that the quick.money could.be the vectoring agents that pmn is able.to produce and that can be for a variety of.diseases ....
<< Previous
Bullboard Posts
Next >>